Medobar refers to Dobasic Hydrazide tablets and Tysudar refers to Pibedil Extended-Release tablets, which are usually required for long-term use in the treatment of Parkinson’s disease, but care should be taken to monitor the side effects of the drugs. Dobasic hydrazide tablets and piribedil extended-release tablets are both commonly used in the treatment of Parkinson’s disease, although their drug mechanism of action is different, but they both have certain drug side effects, long-term application can cause some harm to the patient’s body. Dobasic hydrazide tablets can cause certain effects on the patient’s blood and lymphatic system, nervous system, mental system, heart and gastrointestinal tract. Dobasic hydrazide tablets are prohibited for patients with hepatic or renal dysfunction, psychosis, angle-closure glaucoma, heart disease and pregnancy, and patients under 25 years old. The main side effects of piribedil extended-release tablets are gastrointestinal reactions, postural hypotension and drowsiness. For acute myocardial infarction, cardiogenic shock and patients taking tranquilizer psychotropic drugs is piribedil extended-release tablets are contraindicated. Parkinson’s patients are advised to go to the Neurology Department of regular hospitals for regular follow-up, and adjust the drug type and dosage under the guidance of professional physicians according to the patient’s condition, drug use and reaction to avoid adverse drug reactions.